ReviewPain and therapy2019
The Role of Lofexidine in Management of Opioid Withdrawal.
Review in Pain and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Efficacy and Safety of Alpha-2 Agonists in Autism Spectrum Disorder: A Systematic Review.Advances in therapy · 2024Pooled it
- Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs.Drug and alcohol dependence · 2020Trial
- Trial
- A Review of Alpha-2 Adrenergic Agents Implicated in Opioid Use Disorder.ACS chemical neuroscience · 2026Review
- Mechanism-based nonopioid analgesic targets.The Journal of clinical investigation · 2025Review
- The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists.The American journal of psychiatry · 2024Review
- Cold nociception as a measure of hyperalgesia during spontaneous heroin withdrawal in mice.Pharmacology, biochemistry, and behavior · 2024Article
- A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: Focus on opioid dependence.INNOSC theranostics & pharmacological sciences · 2024Article
- Guanfacine Treatment in a Patient with Intravenous Buprenorphine/Naloxone Misuse.Case reports in psychiatry · 2024Article
- An ensemble recruited by αNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol.Cannabis and cannabinoid research · 2022Review
- Noradrenergic circuits and signaling in substance use disorders.Neuropharmacology · 2022Review
- Autonomic Regulation of Nociceptive and Immunologic Changes in a Mouse Model of Complex Regional Pain Syndrome.The journal of pain · 2022Article
- Neuroscientific Basis of Treatment for Substance Use Disorders.Noro psikiyatri arsivi · 2022Review
- Functional evaluation of NKDrug and alcohol dependence · 2021Article
- Auricular neural stimulation as a new non-invasive treatment for opioid detoxification.Bioelectronic medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fear of withdrawal symptoms has been cited by survey respondents as the main reason that they continued to use opioids. Lofexidine is an α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.